Difference between revisions of "Team:Edinburgh OG/Safety"

Line 6: Line 6:
  
 
<h1 class="subtitle text-center"> Safety </h1>
 
<h1 class="subtitle text-center"> Safety </h1>
<p>Please visit <a href="https://2017.igem.org/Safety">the main Safety page</a> to find this year's safety requirements & deadlines, and to learn about safe & responsible research in iGEM.</p>
+
<p>Safety was one of our top priorities during the design and implementation of our project. Our plan went through several iterations to ensure it met iGEM, university and national safety standards.</p>
 
+
<h2>Safe Project Design</h2>
<p>On this page of your wiki, you should write about how you are addressing any safety issues in your project. The wiki is a place where you can <strong>go beyond the questions on the safety forms</strong>, and write about whatever safety topics are most interesting in your project. (You do not need to copy your safety forms onto this wiki page.)</p>
+
<h3>Proof-of-concept</h3>
 
+
<p>When we first started thinking about our project, we had grand plans to carry out our initial experiments in <em>E. coli</em> before completing proof-of-concept in the ESKAPE pathogens themselves. We soon realised that working with these pathogens was unwise from a safety standpoint, and was not permitted by either iGEM and University of Edinburgh safety guidelines, so we altered our plan and developed new experiments so that all proof-of-concept work could be carried out in non-pathogenic <em>E. coli</em>. We liaised with the University of Edinburgh Biological Safety Committee to create a safe system that would allow us to achieve our goals.</p>
</div>
+
<p>Our first plan for the <em>E. coli</em> system was to use promoter-less resistance genes. Through discussions with the safety committee we realised that the risks of expression due to cryptic promoters or spread through horizontal gene transfer were not insignificant. We altered the design of our system to ensure that no functional resistance gene products would be expressed by using short &ldquo;chunks&rdquo; of the gene, rather than the full sequence.</p>
 
+
<p>We used MoClo to create plasmids bearing short, 51 base pair regions of our chosen antibiotic resistance genes, separated by linker sequences of 6-8 amino acids (Figure 1) and followed by a GFP reporter gene sequence (Figure 2).</p>
 
+
<p><strong>Fig. 1: </strong>Structure of the protospacer DNA system, showing the 4 protospacer chunks (purple, labelled &ldquo;P&rdquo;) separated by linkers. This sequence was combined with the GFP system in Fig. 2 using MoClo.</p>
<div class="column full_size">
+
<p><strong>Fig. 2: </strong>Structure of the GFP system, showing the double terminators used to ensure a complete halting of translation at the desired point. This sequence was combined with the protospacer system in Fig. 1 using MoClo.</p>
<h5>Safe Project Design</h5>
+
<p>The protospacer regions were chosen carefully so as to avoid any active sites that could confer antibiotic resistance to the chassis <em>E. coli</em>, while also maintaining a high level of sequence conservation so that in future this system can be applied to a range of species that possess each gene. The gene regions were placed in a different order than that in which they would be found in a natural system (e.g. 4 2 3 1) to further minimise the chances of any functional protein being formed. The GFP sequence was followed by two terminators (T1 and His terminators from <em>E. coli</em>) to ensure complete halting of translation at the desired point. These were then ligated together in one vector using MoClo assembly (Figure 3).</p>
 
+
<p><strong>Fig.3:</strong> Overview of MoClo assembly with the construct containing the resistant gene regions and construct for <em>GFP</em> being inserted into a DVK-AF plasmid. <strong>A:</strong> Displays construct assembly, BsaI:R indicates the enzyme will cut to the right, BsaI:L indicates it will cut to the left. A, E and F = MoClo fusion sites. <strong>B:</strong> Overview of each construct and DVK-AF once it has been cut by BsaI. <strong>C</strong>: After ligation DVK will contain <em>VanA</em> fused to <em>GFP.</em></p>
<p>Does your project include any safety features? Have you made certain decisions about the design to reduce risks? Write about them here! For example:</p>
+
<p>By using this system, we were able to ensure that our system was safe and that there were no risks of spreading antibiotic resistance through our work. The constructs acted purely as targets for CRISPR, rather than conferring any antibiotic resistance.</p>
 
+
<h2>Safe Lab Work</h2>
<ul>
+
<h3>Risk Assessment</h3>
<li>Choosing a non-pathogenic chassis</li>
+
<p>Risk assessment forms were filled in and signed by each team member to ensure that we were all aware of any safety precautions necessary for our reagents, equipment, and organisms.</p>
<li>Choosing parts that will not harm humans / animals / plants</li>
+
<h3>Chassis</h3>
<li>Substituting safer materials for dangerous materials in a proof-of-concept experiment</li>
+
<p>We used several non-pathogenic <em>E. coli</em> strains as chassis - TOP10, DH5ɑ, C600, RecD-, and BL21 DE3. These strains are not harmful to humans, and were worked on inside a class 1 laboratory following standard laboratory safety procedures. Plates containing <em>E. coli </em>were sealed with parafilm prior to storage at 4&deg;C. Once no longer required, plates were destroyed by autoclaving. All culture waste was treated with Virkon prior to autoclaving.</p>
<li>Including an "induced lethality" or "kill-switch" device</li>
+
<p>We also used several strains of bacteriophages as chassis during our project - P1, &lambda;, and T4. Bacteriophages do not infect human cells, and the strains that we used were specific to <em>E. coli</em>. While this meant that they did not pose a threat to us, there was still a risk of contaminating the laboratory and unintentionally killing <em>E. coli</em> that other researchers were using/storing. Therefore, all work with phages was carried out in a class 2 cabinet, housed in a class 1 laboratory separate to the rest of our work. Phages were not removed from this lab, and all equipment was sterilised by ethanol/autoclaving before being moved out of the lab.</p>
</ul>
+
<h3>Reagents</h3>
 
+
<p>Chloroform was used in phage purification procedures. All chloroform work was carried out in the fume hood.</p>
</div>
+
<h3>PPE</h3>
 
+
<p>Lab coats and gloves were worn at all times during the lab. Face masks were worn when working with powdered reagents such as kanamycin. Long hair was tied back, and closed-toe shoes were worn in the lab. Where cultures/reagents had to be transported between buildings, they were carried in sealed containers. Protective gloves were worn when handling hot glassware. PPE was removed and hands were thoroughly washed prior to exiting the lab.</p>
<div class="column half_size">
+
<h2>Safe Shipment</h2>
<h5>Safe Lab Work</h5>
+
<p>Our DNA was shipped to the Registry according to the guidelines and requirements set out by iGEM.</p>
 
+
<p>What safety procedures do you use every day in the lab? Did you perform any unusual experiments, or face any unusual safety issues? Write about them here!</p>
+
 
+
</div>
+
 
+
<div class="column half_size">
+
<h5>Safe Shipment</h5>
+
 
+
<p>Did you face any safety problems in sending your DNA parts to the Registry? How did you solve those problems?</p>
+
</div>
+
 
+
  
 
</html>
 
</html>

Revision as of 19:39, 28 October 2017

PhagED: a molecular toolkit to re-sensitise ESKAPE pathogens

Safety

Safety was one of our top priorities during the design and implementation of our project. Our plan went through several iterations to ensure it met iGEM, university and national safety standards.

Safe Project Design

Proof-of-concept

When we first started thinking about our project, we had grand plans to carry out our initial experiments in E. coli before completing proof-of-concept in the ESKAPE pathogens themselves. We soon realised that working with these pathogens was unwise from a safety standpoint, and was not permitted by either iGEM and University of Edinburgh safety guidelines, so we altered our plan and developed new experiments so that all proof-of-concept work could be carried out in non-pathogenic E. coli. We liaised with the University of Edinburgh Biological Safety Committee to create a safe system that would allow us to achieve our goals.

Our first plan for the E. coli system was to use promoter-less resistance genes. Through discussions with the safety committee we realised that the risks of expression due to cryptic promoters or spread through horizontal gene transfer were not insignificant. We altered the design of our system to ensure that no functional resistance gene products would be expressed by using short “chunks” of the gene, rather than the full sequence.

We used MoClo to create plasmids bearing short, 51 base pair regions of our chosen antibiotic resistance genes, separated by linker sequences of 6-8 amino acids (Figure 1) and followed by a GFP reporter gene sequence (Figure 2).

Fig. 1: Structure of the protospacer DNA system, showing the 4 protospacer chunks (purple, labelled “P”) separated by linkers. This sequence was combined with the GFP system in Fig. 2 using MoClo.

Fig. 2: Structure of the GFP system, showing the double terminators used to ensure a complete halting of translation at the desired point. This sequence was combined with the protospacer system in Fig. 1 using MoClo.

The protospacer regions were chosen carefully so as to avoid any active sites that could confer antibiotic resistance to the chassis E. coli, while also maintaining a high level of sequence conservation so that in future this system can be applied to a range of species that possess each gene. The gene regions were placed in a different order than that in which they would be found in a natural system (e.g. 4 2 3 1) to further minimise the chances of any functional protein being formed. The GFP sequence was followed by two terminators (T1 and His terminators from E. coli) to ensure complete halting of translation at the desired point. These were then ligated together in one vector using MoClo assembly (Figure 3).

Fig.3: Overview of MoClo assembly with the construct containing the resistant gene regions and construct for GFP being inserted into a DVK-AF plasmid. A: Displays construct assembly, BsaI:R indicates the enzyme will cut to the right, BsaI:L indicates it will cut to the left. A, E and F = MoClo fusion sites. B: Overview of each construct and DVK-AF once it has been cut by BsaI. C: After ligation DVK will contain VanA fused to GFP.

By using this system, we were able to ensure that our system was safe and that there were no risks of spreading antibiotic resistance through our work. The constructs acted purely as targets for CRISPR, rather than conferring any antibiotic resistance.

Safe Lab Work

Risk Assessment

Risk assessment forms were filled in and signed by each team member to ensure that we were all aware of any safety precautions necessary for our reagents, equipment, and organisms.

Chassis

We used several non-pathogenic E. coli strains as chassis - TOP10, DH5ɑ, C600, RecD-, and BL21 DE3. These strains are not harmful to humans, and were worked on inside a class 1 laboratory following standard laboratory safety procedures. Plates containing E. coli were sealed with parafilm prior to storage at 4°C. Once no longer required, plates were destroyed by autoclaving. All culture waste was treated with Virkon prior to autoclaving.

We also used several strains of bacteriophages as chassis during our project - P1, λ, and T4. Bacteriophages do not infect human cells, and the strains that we used were specific to E. coli. While this meant that they did not pose a threat to us, there was still a risk of contaminating the laboratory and unintentionally killing E. coli that other researchers were using/storing. Therefore, all work with phages was carried out in a class 2 cabinet, housed in a class 1 laboratory separate to the rest of our work. Phages were not removed from this lab, and all equipment was sterilised by ethanol/autoclaving before being moved out of the lab.

Reagents

Chloroform was used in phage purification procedures. All chloroform work was carried out in the fume hood.

PPE

Lab coats and gloves were worn at all times during the lab. Face masks were worn when working with powdered reagents such as kanamycin. Long hair was tied back, and closed-toe shoes were worn in the lab. Where cultures/reagents had to be transported between buildings, they were carried in sealed containers. Protective gloves were worn when handling hot glassware. PPE was removed and hands were thoroughly washed prior to exiting the lab.

Safe Shipment

Our DNA was shipped to the Registry according to the guidelines and requirements set out by iGEM.